AxoGen Stock

AxoGen EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of AxoGen (AXGN) as of Sep 6, 2026 is 2,109.04. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 377.88 — a change of 458.12% (higher).

EV/OCF

2,109.04

YoY

458.12%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of AxoGen is 2026 2,109.04 . EV/OCF (Enterprise Value to Operating Cash Flow) of AxoGen was 2025 377.88 . It decreases by 458.12% higher compared to the previous year.

The AxoGen EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-88.63 USD
Jan 1, 2019
-80.67 USD
Jan 1, 2020
-169.10 USD
Jan 1, 2021
-123.86 USD
Jan 1, 2022
-105.60 USD
Jan 1, 2023
-300.08 USD
Jan 1, 2024
377.88 USD
Jan 1, 2025
2,109.04 USD
The AxoGen EV/OCF history
YEAREV/OCFYoY
2,109.04+458.12%
377.88-225.93%
-300.08+184.17%
-105.60-14.74%
-123.86-26.75%
-169.10+109.61%
-80.67-8.98%
-88.63-51.49%
-182.69+20.84%
-151.18+16.18%
-130.13-20.77%
-164.24
Access this data via the Eulerpool API

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AxoGen stock

EV/OCF (Enterprise Value to Operating Cash Flow) of AxoGen is 2,109.04 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of AxoGen changed from 377.88 to 2,109.04, representing a 458.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) AxoGen since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s AxoGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — AxoGen

All Key Metrics — AxoGen